Tadalafil inclusion in microporous silica as effective dissolution enhancer: Optimization of loading procedure and molecular state characterization

Journal of Pharmaceutical Sciences

Volumn 100, Issue 5, 2011, Pages 1805-1818

  Mehanna, Mohammed M ^a   Motawaa, Adel M ^a   Samaha, Magda W ^a  

^a Alexandria University Faculty of Pharmacy   (Egypt)

Author keywords

Amorphous; Dissolution; Inclusions; Mathematical model; Solid state

Indexed keywords

SILICON DIOXIDE; TADALAFIL;

ARTICLE; CRYSTALLIZATION; DIFFERENTIAL SCANNING CALORIMETRY; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; DRUG STORAGE; INFRARED SPECTROSCOPY; POROSITY; RESPONSE SURFACE METHOD; THERMOGRAVIMETRY; X RAY DIFFRACTION;

EID: 79952234982     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22420     Document Type: Article

References (52)

1. Brock GB, McMahon CG, Chen KK. 2002. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: Results of integrated analysis. J Urol 168:1332-1336.
2. Lin CS, Chow S, Lau AR. 2002. Human PDE5A gene encodes three PDE5 isoforms from two alternate promoters. Int J Impot Res 14:15-24.
3. Coward RM, Carson CC. 2008. Tadalafil in the treatment of erectile dysfunction. Ther Clin Risk Manag 4:315-329.
4. Chavda HV, Patel CN, Anand IS. 2010. Biopharmaceutics classification system. Syst Rev Pharm 1:62-69.
5. Carson CC. 2007. Phosphodiesterase type 5 inhibitors: State of the therapeutic class. Urol Clin North Am 34:507-515.
6. Stegemanna S, Leveiller F, Franchic D, De Jongd H, Linden H. 2007. When poor solubility becomes an issue: From early stage to proof of concept. Eur J Pharm Sci 31:249-261.
7. Saharan VA, Kukkar V, Kataria M, Gera M, Choudhury PK. 2009. Dissolution enhancement of drugs part II: Effect of carriers. Int J Health Res 2:207-223.
8. Mehanna MM, Motawaa AM, Samaha MW, 2010. In sight into tadalafil-block copolymer binary solid dispersion: Mechanistic investigation of dissolution enhancement. Int J Pharm 402:78-88.
9. Song S-W, Hidajat K, Kawi S. 2005. Functionalized SAB-15 material as carrier for controlled drug delivery: Influence of surface properties on matrix-drug interactions. Langmuir 21:9568-9575.
10. Li Z, Wen L, Shao L, Chen J. 2004. Fabrication of porous hollow silica nanoparticles and their applications in drug release control. J Control Release 98:244-254.
11. Streubel A, Sipemann J, Bodmeier R. 2003. Multiple unit gastroretentive drug delivery systems: A new method for low density microparticles. J Microencapsul 20:329-347.
12. Murakami T, Yata N. 1995. Controlled drug release by the use of porous calcium silicate. Drug Del Syst 10:159-166.
13. Ito Y, Arai H, Uchino K, Iwasaki K, Shibata N, Takada K. 2005. Effect of adsorbents on the absorption of lansoprazole with surfactant. Int J Pharm 289:69-77.
14. Byrne RS, Deasy PB. 2002. Use of commercial porous ceramic particles for sustained drug delivery. Int J Pharm. 246:61-73.
15. 3 microparticles and encapsulation by polyelectrolyte multilayer films for sustained drug delivery. Int J Pharm 308:160-167.
16. Lewis GA, Mathieu D, Phan-Tan-Luu R, Pharmaceutical experimental design. 1999, New York: Marcel Dekker Inc.
17. Mehanna MM, Elmaradny HA, Samaha MS. 2009. Ciprofloxacin liposomes as vesicular reservoirs for ocular delivery: formulation, optimization, and in vitro characterization. Drug Dev Ind Pharm 35:583-593.
18. Lin Y-C, Fregly BJ, Haftka RT, Queipo NV. 2005. Surrogate-based contact modelling for efficient dynamic simulation with deformable anatomic joints. In Tenth International Symposium on Computer Simulation in Biomechanics. Cleveland, Ohio.
19. Carriazo D, Del Arco M, Fernandez A, Martin C, Rives V. 2010. Inclusion and release of fenbufen in mesoporous silica. J Pharm Sci 1-9.
20. Giunta AA, Wojtkiewicz SF, Eldred MS. 2003. Overview of modern design of experiments methods for computational simulations (AIAA 2003-0649)by American Institute of Aeronautics and Astronautics, Sandia National Laboratories. Albuquerque, New Mexico.
21. Giannakou SA, Dallas PP, Rekkas DM, Choulis NH. 2002. In vitro evaluation of nimodipine permeation through human epidermis using response surface methodology. Int J Pharm 241:27-34.
22. Lewis GA, Mathieu D, Phan-Tan-Luu R. 1999. Response surface methodology. In Pharmaceutical experimental design., Swarbrick, J. Ed. New York: Marcel Dekker Inc., pp 185-246.
23. Pikal MJ, Lukes AL, Lang JE, Gaines K. 1978. Quantitative crystallinity determinations for beta-lactam antibiotics by solution calorimetry: Correlation with stability. J Pharm Sci 67:767-773.
24. Brunauer S, Emmet PH, Teller E. 1938. Adsorption of gases in multimolecular layers. J Am Chem Soc 60:309-319.
25. Choma J, Jaroniec M., Burakiewicz-Mortka W, Kloske M. 2002. Critical appraisal of classical methods for determination of mesopore size distributions of MCM-41 materials. Appl Surf Sci 196:216-223.
26. Jaroniec M, Kruk M, Olivier JP. 1999. Standard nitrogen adsorption data for characterization of nanoporous silica. Langmuir 15:5410-5413.
27. Guidance for industry Q1A stability testing of new drug substances and products, at 2010, U.S. Department of Health and Human Services Food and Drug administration.
28. Tingming F, Liwei G, Kang L, Tianyao W, Jin L. 2010. Template occluded SBA-15: An effective dissolution enhancer for poorly water-soluble drug. Appl Surf Sci 256:6963-6968.
29. Arima H, Yunomae K, Miyake K, Irie T, Hirayama F, Uekama K, 2001. Comparative studies of the enhancing effects of cyclodextrins on the solubility and oral bioavailability of tacrolimus in rats. J Pharm Sci 90:690-701.
30. Loftsson T, Magnusdottir A, Masson M, Sigurjonsdottir JF, 2002. Self association and cyclodextrin solubilization of drugs. J Pharm Sci 91:2307-2316.
31. Loftsson T, Masson M, Brewster ME. 2004. Self association of cyclodextrin and cyclodextrin complexes. J Pharm Sci 93:1091-1099.
32. Comerton AM, Andrews RC, Bagley DM. 2009. The influence of natural organic matter and cations on the rejection of endocrine disrupting and pharmaceutically active compounds by nanofiltration. Water Res 43:613-622.
33. Kulshrestha P, Giese RF, Aga DS. 2004. Investigating the molecular interactions of oxytetracycline in clay and organic matter: Insights on factors affecting its mobility in soil. Environ Sci Technol 38:4097-4105.
34. Pils JRV, Laird DA. 2007. Sorption of tetracycline and chlortetracycline on K- and Ca-saturated soil clays, humic substances, and clay-humic complexes. Environ Sci Technol 41:1928-1933.
35. Tulp HC, Fenner K, Schwarzenbach RP, Goss K-U. 2009. pH-dependent sorption of acidic organic chemicals to soil organic matter. Environ Sci Technol 43:9189-9195.
36. Hancock BC, Zografi G. 1997. Characteristics and significance of the amorphous state in pharmaceutical systems. J Pharm Sci 86:1-12.
37. Van Damme H 2000Nanoscale and mesoscale morphology of silica surfaces. In Adsorption on silica surfaces; Papirer, E, Ed., New York: Marcel Dekker Inc., pp 119-165.
38. Xia W, Chang J, 2006. Well-ordered mesoporous bioactive glasses (MBG): A promising bioactive drug delivery system. J Control Release 110:522-530.
39. Miura H, Kanebako M, Shirai H, Nakao H, Inagi T, Terada K. 2010. Enhancement of dissolution rate and oral absorption of a poorly water-soluble drug, K-832, by adsorption onto porous silica using supercritical carbon dioxide. Eur J Pharm Biopharm 76:215-221.
40. Sanganwar GP, Gupta RB. 2008. Dissolution-rate enhancement of fenofibrate by adsorption onto silica using supercritical carbon dioxide. Int J Pharm 360:213-218.
41. Williams RO, Mahaguna V, Sriwongjanya M. 1998. Characterization of a inclusion complex of cholesterol and hydroxypropyl-b-cyclodextrin. Eur J Pharm Biopharm 46:355-360.
42. Ambrogi V, Perioli L, Marmottini F, Accorsi O, Pagano C, Ricci M, Rossi C, 2008. Role of mesoporous silicates on carbamazepine dissolution rate enhancement. Microporous Mesoporous Mater 113:445-452.
43. Sliwinska-Bartkowiak M, Dudziak G, Gras R, Sikorski R, Radhakrishnan R, Gubbins KE. 2001. Freezing behavior in porous glasses and MCM 41. Colloid Surf A Physicochem Eng Asp 187-188:523-529.
44. Ambrogi V, Perioli L, Marmottini F, Giovagnoli S, Esposito M, Rossi C. 2007. Improvement of dissolution rate of piroxicam by inclusion into MCM-41 mesoporous silicate. Eur J Pharm Sci 32:216-222.
45. Matsumoto K, Nakai Y, Yonemochi E, Oguchi T, Yamamoto K. 1998. Effect of pore size on the gaseous adsorption on ethenzamide on porous crystalline cellulose and the physicochemical stability of ethenzamide after storage. Chem Pharm Bull 46:314-318.
46. Yonemochi E, Kojinma M, Nakatsuji A, Okonogi S, Oguchi T, Nakai Y, Yamamoto K. 1995. Thermal behavior of methyl phydroxybenzoate in controlled-pore glass solid dispersion. J Colloid Interface Sci 173:186-191.
47. Tozuka Y, Oguchi T, Yamamoto K. 2003. Adsorption and entrapment of salicylamide molecules into the mesoporous structure of folded sheets mesoporous material (FSM-16). Pharm Res 20:926-930.
48. Mellaerts R, Mols R, Jammaer JAG, Aerts CA, Annaert P, Humbeeck JV, Van Den Mooter G, Augustijns P, Martens JA. 2008. Increasing the oral bioavailability of the poorly water soluble drug itraconazole with ordered mesoporous silica. Eur J Pharm Biopharm 69:223-230.
49. Salonen J, Laitinen L, Kaukonen AM. 2005. Mesoporous silicon microparticles for oral drug delivery: Loading and release of five model drugs. J Control Release 108:362-374.
50. Froster A, Hempenstall J, Rades T. 2001. Characterization of glass solutions of poorly water-soluble drugs produced by melt extrusion with amorphous polymers. J Pharm Pharmacol 53:303-315.
51. Kaushal AM, Gupta P, Bansal AK. 2004. Amorphous drug delivery systems: Molecular aspects, design, and performance. Crit Rev Ther Drug Carrier Syst 21:133-193.
52. Rustichelli C, Gamberoni G, Ferioli V, Gamberini MC, Ficarra R, Tommassini S. 2000. Solid-state study of polymorphic drugs: carbamazepine. J Pharm Biomed Anal 23:41-54.